66
Participants
Start Date
December 6, 2022
Primary Completion Date
March 18, 2025
Study Completion Date
April 18, 2025
Reparixin 600mg
Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
Matching Placebo
"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
Universitaetsklinikum Leipzig, Leipzig
Berufsgenossenschaftliche Kliniken Bergmannstrost, Halle
New York University Langone Health, New York
NYU Langone Brooklyn, Brooklyn
Ospedale San Raffaele, Milan
Virginia Commonwealth University Health System, Richmond
University Hospital of Schleswig-Holstein, Kiel
Emory Saint Joseph's Hospital, Atlanta
University of South Florida, Tampa
The University of Alabama at Birmingham Hospital, Birmingham
Universitaetsmedizin Goettingen, Göttingen
University of Tennessee Medical Center, Knoxville
Jackson Pulmonary Associates, Jackson
The Ohio State University Wexner Medical Center, Columbus
The Cleveland Clinic Foundation, Cleveland
Methodist Hospitals of Northwest Indiana, Gary
William Beaumont Hospital, Royal Oak
Herzzentrum Muenster, Münster
Detroit Medical Center, Detroit
Henry Ford Hospital, Detroit
MyMichigan Medical Center Midland, Midland
Medical College of Wisconsin, Milwaukee
University of Missouri Health Care, Columbia
Universitaetsklinikum Heidelberg, Heidelberg
University of Oklahoma Medical Center, Oklahoma City
Cardiovoyage, Denison
Houston Methodist Hospital, Houston
Baptist Hospitals of Southeast Texas, Beaumont
Denver Health, Denver
University of Utah Hospitals & Clinics, Salt Lake City
Banner - University Medical Center Phoenix, Phoenix
University of Southern California, Los Angeles
University of California Irvine Health, Orange
Unversity of California Davis Medical Center, Sacramento
Oregon Health and Science University, Portland
Beth Israel Deaconess Medical Center, Boston
Newton Wellesley Hospital, Newton
Baystate Health, Springfield
Hackensack Meridian Health, Hackensack
University of Texas Southwestern Medical Center, Dallas
Dompé Farmaceutici S.p.A
INDUSTRY